Riley Griffin And Jef Feeley Bloomberg

Johnson & Johnson said it plans to stop selling its legacy talc-based baby-powder products globally in 2023, a move that comes amid continued legal battles and years after the company discontinued the product in the US and Canada.

The first prosecution of a pharmaceutical company chief executive tied to opioid overdoses begins this week, when Insys Therapeutics Inc.'s John Kapoor goes on trial. The fallout may jolt an industry facing steep penalties for its own role in the crisis.

Johnson & Johnson said it plans to stop selling its legacy talc-based baby-powder products globally in 2023, a move that comes amid continued legal battles and years after the company discontinued the product in the US and Canada.

The first prosecution of a pharmaceutical company chief executive tied to opioid overdoses begins this week, when Insys Therapeutics Inc.'s John Kapoor goes on trial. The fallout may jolt an industry facing steep penalties for its own role in the crisis.